Skip to main content
Midas Edge

OmniAb, Inc.

For the period ended Dec 31, 2024. Filed Mar 18, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 18, 2025

OABI$5.10-3.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 16. Form 10-K Summary

None

EXHIBIT INDEX

Incorporated by Reference
ExhibitNumber · Description of Exhibit · Form · File Number · Date of Filing · Exhibit Number · Filed Herewith
2.1+Agreement and Plan of Merger, dated March 23, 2022, by and among Avista Public Acquisition Corp. II, Orwell Merger Sub Inc., Ligand Pharmaceuticals Incorporated and OmniAb, Inc.S-4333-264525September 27, 20222.1
2.2+Separation and Distribution Agreement, dated March 23, 2022, by and among Avista Public Acquisition Corp. II, Ligand Pharmaceuticals Incorporated and OmniAb, Inc.S-4333-264525September 27, 20222.2
3.1Certificate of Incorporation of the Registrant10-K001-40720March 30, 20233.1
3.2Bylaws of the Registrant8-K001-40720November 7, 20223.2
4.1Warrant Agreement, dated August 9, 2021, between Avista Public Acquisition Corp. II and Continental Stock Transfer & Trust Company, as warrant agent8-K001-40720August 12, 20214.1
4.2Assignment, Assumption and Amendment Agreement, dated November 1, 2022, by and among OmniAb, Inc., Continental Stock Transfer & Trust Company and Computershare Trust Company, N.A.8-K001-40720November 7, 20224.2
4.3Specimen Warrant CertificateS-1/A333-257177July 28, 20214.3
4.4Specimen Common Stock Certificate of OmniAb, Inc.S-4333-264525September 27, 20224.5
4.5Description of Registered Securities10-K001-40720March 30, 20234.5
10.1Private Placement Warrants Purchase Agreement, dated August 9, 2021, between Avista Public Acquisition Corp. II and Avista Acquisition LP II8-K001-40720August 12, 202110.3
10.2#Form of Letter Agreements, dated August 9, 2021, by and among Avista Public Acquisition Corp. II, each of Avista Public Acquisition Corp. II’s officers and directors and Avista Acquisition LP II8-K001-40720August 12, 202110.5
10.3#Form of Indemnity Agreements, dated August 9, 2021, between Avista Public Acquisition Corp. II, each of its officers and directors and Avista Acquisition LP II8-K001-40720August 12, 202110.6
10.4Securities Subscription Agreement, dated February 12, 2021, between Avista Public Acquisition Corp. II and the SponsorS-1/A333-257177July 28, 202110.7
10.5Sponsor Insider Agreement, dated March 23, 2022, by and among OmniAb, Inc., Avista Public Acquisition Corp. II, Avista Acquisition LP II and the other parties signatory theretoS-4333-264525September 27, 202210.11
10.6†Amended and Restated Registration and Stockholder Rights Agreement, dated November 1, 2022 by and among OmniAb, Inc., Avista Acquisition LP II and the other parties named therein8-K001-40720November 7, 202210.7
10.7Amended and Restated Forward Purchase Agreement, dated March 23, 2022, by and among Avista Public Acquisition Corp. II, Avista Acquisition LP II and OmniAb, Inc.S-4333-264525September 27, 202210.12
10.8+Amended and Restated Employee Matters Agreement, dated August 18, 2022, by and among Avista Public Acquisition Corp. II, Orwell Merger Sub Inc., Ligand Pharmaceuticals Incorporated and OmniAb, Inc.S-4333-264525September 27, 202210.13
10.9†+Tax Matters Agreement, dated November 1, 2022, by and among OmniAb, Inc., Ligand Pharmaceuticals Incorporated and OmniAb Operations, Inc.8-K001-40720November 7, 202210.10
10.10#OmniAb, Inc. 2022 Incentive Award Plan8-K001-40720October 24, 202210.1
10.11#Form of Stock Option Agreement under the OmniAb, Inc. 2022 Incentive Award Plan8-K001-40720November 7, 202210.14
10.12#Form of Restricted Stock Unit Agreement under the OmniAb, Inc. 2022 Incentive Award Plan8-K001-40720November 7, 202210.15
10.13#Form of Performance Stock Unit Agreement under the OmniAb, Inc. 2022 Incentive Award Plan8-K001-40720November 7, 202210.16
10.14#OmniAb, Inc. 2022 Employee Stock Purchase Plan8-K001-40720October 24, 202210.2
10.15#OmniAb, Inc. 2022 Ligand Service Provider Assumed Award Plan8-K001-40720November 7, 202210.18
10.16#OmniAb, Inc. 2022 OmniAb Service Provider Assumed Award Plan8-K001-40720November 7, 202210.19
10.17#OmniAb, Inc. Director Compensation and Stock Ownership Policy (as amended and restated effective June 1, 2023)10-Q001-40720August 10, 202310.1
10.18#OmniAb, Inc. Severance Plan8-K001-40720November 7, 202210.21
10.19#Change in Control Severance Agreement, effective November 1, 2022, between OmniAb, Inc. and Matthew W. Foehr10-K001-40720March 30, 202310.21
10.20#Change in Control Severance Agreement, effective November 1, 2022, between OmniAb, Inc. and Kurt A. Gustafson10-K001-40720March 30, 202310.22
10.21#Change in Control Severance Agreement, effective November 1, 2022, between OmniAb, Inc. and Charles S. Berkman10-K001-40720March 30, 202310.23
10.22#Form of OmniAb, Inc. Indemnification Agreement for Directors and OfficersS-4333-264525September 27, 202210.25
10.23+Office/Laboratory Lease between Emery Station Office II, LLC and Ligand Pharmaceuticals Incorporated, dated June 8, 2021S-4333-264525September 27, 202210.26
10.24†Assignment of Lease, Consent to Assignment of Lease and First Amendment to Lease, dated for reference purposes only as of October 26, 2022, by Emery Station Office II, LLC, Ligand Pharmaceuticals Incorporated and OmniAb, Inc.10-K001-40720March 30, 202310.26
10.25Open Market Sale Agreement℠, dated December 8, 2023, between the Company and Jefferies LLCS-3333-275966December 8, 20231.2
19Insider Trading Compliance Policy and Procedures, as amended and restated effective March 28, 2023X
21.1List of Subsidiaries of OmniAb, Inc.8-K/A001-40720November 7, 202221.1
23.1Consent of Ernst & Young LLPX
31.1Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X
31.2Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X
32.1*Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
32.2*Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
97Policy for Recovery of Erroneously Awarded Compensation10-K001-40720March 25, 202497
101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL documentX
101.SCHInline XBRL Taxonomy Extension Schema DocumentX
101.CALInline XBRL Taxonomy Calculation Linkbase DocumentX
101.DEFInline XBRL Taxonomy Definition Linkbase DocumentX
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentX
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentX
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)X
  • Certain schedules and annexes have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or annex will be furnished as a supplement to the SEC upon request.

#Indicates management contract or compensatory plan.

†Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions are (i) not material and (ii) treated by the Registrant as private or confidential.

*This certification is deemed not filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.